Table 1 Results of univariable analyses on demographic, clinical and psychosocial baseline variables
|  | No use of psychosocial support services (n = 279)(n,%) | Use of psychosocial support services (n = 70)(n,%) | p-value |
|---|---|---|---|
Age, years | Â | Â | *0.003 |
Mean age (SD) | 66.92 (9.7) | 62.74 (11.41) | Â |
Gender | Â | Â | 0.415 |
 Male | 182 (65.2) | 42 (60.0) |  |
 Female | 97 (34.8) | 28 (40.0) | |
Treatment arm in TES trial | Â | Â | 0.610 |
 Intervention | 149 (53.4) | 35 (50) |  |
 Control | 130 (46.6) | 35 (50) | |
ECOG PSa | Â | Â | 0.714 |
 0 | 67 (24.0) | 15 (21.4) |  |
 1 | 87 (31.2) | 18 (25.7) | |
 2 | 8 (2.9) | 3 (4.3) | |
 Missing | 117 (41.9) | 34 (48.6) | |
Primary tumor location | Â | Â | 0.695 |
 Right-sided | 84 (30.1) | 23 (32.9) |  |
 Left-sided | 192 (68.8) | 47 (67.1) | |
 Missing | 3 (1.1) | – | |
Chemotherapy regimen | Â | Â | 0.875 |
 Capecitabine | 59 (21.1) | 13 (18.6) |  |
 CAPOX | 190 (68.1) | 50 (71.4) | |
 FOLFOX/Other | 27 (9.7) | 7 (10.0) | |
 Missing | 3 (1.1) | – | |
Number of comorbidities | Â | Â | 0.980 |
 Mean (SD) | 2.33 (1.78) | 2.33 (2.00) |  |
Marital status | Â | Â | 0.369 |
 Married/domestic partnership | 207 (74.2) | 49 (70.0) |  |
 Unmarried/divorced/widowed | 68 (24.4) | 21 (30.0) | |
 Missing | 4 (1.4) | – | |
Number of persons in household | Â | Â | 0.615 |
 1 | 49 (17.6) | 13 (18.6) |  |
 2 | 177 (63.4) | 42 (60.0) | |
 3 | 23 (8.2) | 4 (5.7) | |
  > 3 | 26 (9.3) | 11 (15.7) | |
 Missing | 4 (1.4) | – | |
Educationb | Â | Â | *0.041 |
 Low | 17 (6.1) | 2 (2.9) |  |
 Middle | 184 (65.9) | 39 (55.7) | |
 High | 72 (25.8) | 29 (41.4) | |
 Missing | 6 (2.2) | 0 (0) | |
Currently working | Â | Â | 0.949 |
 Yes | 65 (23.3) | 16 (22.9) |  |
 No/retired | 210 (75.3) | 54 (77.1) | |
 Missing | 4 (1.4) | – | |
Time from diagnosis primary tumor until start study | Â | Â | 0.848 |
  < 1.5 months | 94 (33.7) | 22 (31.4) |  |
 1.5–10 months | 89 (31.9) | 25 (35.7) | |
  > 10 months | 93 (33.3) | 23 (32.9) | |
 Missing | 3 (1.1) | – | |
Time from diagnosis metastatic disease until start study | Â | Â | 0.666 |
  < 1.0 months | 95 (34.1) | 27 (38.6) |  |
 1.0–2.5 months | 87 (31.2) | 23 (32.9) | |
  > 2.5 months | 94 (33.7) | 20 (28.6) | |
 Missing | 3 (1.1) | – | |
Prior cancer related treatment | |||
 No | 85 (30.5) | 23 (32.9) | 0.699 |
 Yes | 194 (69.5 | 47 (67.1) | |
Prior treatment metastases | |||
 No | 214 (76.7) | 56 (80.0) | 0.657 |
 Yes | 62 (22.2) | 14 (20.0) | |
 Missing | 3 (1.1) | – | |
Number of organs with metastases | Â | Â | 0.599 |
 Median | 2 | 2 |  |
Total number of metastases | |||
 Median | 11.5 | 13.0 | 0.877 |
Participation in other trials | Â | Â | 0.718 |
 No | 170 (60.9) | 41 (58.6) |  |
 Yes | 109 (39.1) | 29 (41.4) | |
HADS | |||
 Total score | 9.10 (6.30) | 11.17 (7.47) | *0.020 |
 Distress on HADS No | 208 (74.6) | 44 (62.9) | *0.033 |
  Yes | 67 (24.0) | 26 (37.1) |  |
  Missing | 4 (1.4) | – | |
DT/PL | |||
 DT score | 4.33 (2.68) | 4.75 (2.40) | *0.242 |
 Total of physical problems | 5.78 (6.29) | 7.37 (4.61) | *0.020 |
 Total of emotional problems | 1.95 (2.11) | 2.74 (2.57) | *0.009 |
 Need to talk to professional No | 257 (92.1) | 58 (82.9) | *0.023 |
  Yes | 22 (7.9) | 12 (17.1) |  |
Quality of life (QLQ-C30) | |||
 Physical functioning | 74.84 (20.30) | 72.76 (21.88) | 0.451 |
 Role functioning | 65.69 (30.70) | 58.81 (30.13) | *0.010 |
 Emotional functioning | 78.25 (18.12) | 72.86 (21.41) | *0.095 |
 Cognitive functioning | 89.44 (14.97) | 86.90 (16.76) | *0.219 |
 Social functioning | 78.08 (23.89) | 69.05 (31.38) | *0.010 |
 Global QOL | 63.77 (21.73) | 60.00 (21.78) | *0.197 |
 Pain score | 16.00 (23.75) | 40.15 (26.57) | *0.174 |
 Fatigue score | 25.00 (16.67) | 45.08 (44.44) | *0.009 |